Perren T J, Swart A M, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer[J]. N Engl J Med, 2011, 365(26): 2484-2496. [2]Carthew R W, Sontheimer E J. Origins and mechanisms of miRNAs and siRNAs[J]. Cell, 2009, 136(4): 642-655. [3]Croce C M. Causes and consequences of microRNA dysregulation in cancer[J]. Nat Rev Genet, 2009, 10(10): 704-714. [4]Mendell J T. miRiad roles for the miR-17-92 cluster in development and disease[J]. Cell, 2008, 133(2): 217-222. [5]Yan H, Wu J, Liu W, et al. MicroRNA-20a overexpression inhibited proliferation and metastasis of pancreatic carcinoma cells[J]. Hum Gene Ther, 2010, 21(12): 1723-1734. [6]Fan M Q, Huang C B, Gu Y, et al. Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2013, 32(1): 21. [7]Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J]. Cancer Res, 2004, 64(11): 3753-3756. [8]Reinhart B J, Slack F J, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans[J]. Nature, 2000, 403(6772): 901-906. [9]Li X, Pan J H, Song B, et al. Suppression of CX43 expression by miR-20a in the progression of human prostate cancer[J]. Cancer Biol Ther, 2012, 13(10): 890-898. [10]Fischer J E, Bachmann L M, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis[J]. Intensive Care Med, 2003, 29(7): 1043-1051. [11]Volinia S, Calin G A, Liu C G, et al. A microRNA expression signature of human solid tumors defines cancer gene targets[J]. Proc Natl Acad Sci U S A, 2006, 103(7): 2257-2261. [12]Schetter A J, Leung S Y, Sohn J J, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma[J]. JAMA, 2008, 299(4): 425-436. [13]Malzkorn B, Wolter M, Liesenberg F, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas[J]. Brain Pathol, 2010, 20(3): 539-550. [14]Matsubara H, Takeuchi T, Nishikawa E, et al. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92[J]. Oncogene, 2007, 26(41): 6099- 6105. [15]Li X, Zhang Z, Yu M, et al. Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2)[J]. Int J Mol Sci, 2013, 14(8): 16226-16239. [16]O’Donnell K A, Wentzel E A, Zeller K I, et al. c-Myc-regulated microRNAs modulate E2F1 expression[J]. Nature, 2005, 435(7043): 839-843. [17]Ebelt H, Hufnagel N, Neuhaus P, et al. Divergent siblings: E2F2 and E2F4 but not E2F1 and E2F3 induce DNA synthesis in cardiomyocytes without activation of apoptosis[J]. Circ Res, 2005, 96(5): 509-517. [18]Kumar M S, Erkeland S J, Pester R E, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family[J]. Proc Natl Acad Sci U S A, 2008, 105(10): 3903-3908. [19]Droge P, Davey C A. Do cells let-7 determine stemness?[J]. Cell Stem Cell, 2008, 2(1): 8-9. [20]Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008, 18(10): 997-1006. [21]Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review[J]. Gynecol Oncol, 2011, 120(1): 152-157.
